23andMe gains after CEO Wojcicki makes revised $2.94/share offer with CVR

Stock Information for 23andMe Holding Co.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About 23andMe Holding Co.

23andMe Confirms All Potential Buyers Must Agree to Comply With Privacy Policy and Applicable Law
23andMe Launches New Homocysteine (MTHFR-Related) Genetic Report and Accompanying Lab Test
23andMe Special Committee Rejects Acquisition Proposal From CEO Anne Wojcicki
23andMe Launches New Genetic Report on Osteoporosis
23andMe Special Committee Announces Exploration of Strategic Alternatives
23andMe Reports Third Quarter Fiscal Year 2025 Financial Results
23andMe Launches Discover23 to Help Accelerate Large-Scale Genetics Research For Biopharma Collaborators, Powered By Lifebit's Trusted Technology
23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador's Precision Medicines for Immunology & Inflammation

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.